5 Best 52-Week High Stocks To Buy Now

2. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Number of Hedge Fund Holders: 56

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares have gained about 37% over the past one year. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is hovering near its 52-week highs. Earlier in August Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s pozelimab for treatment of the rare immune disease CHAPLE disease won approval from US FDA.

As of the end of the second quarter of 2023, 56 hedge funds out of the 910 tracked by Insider Monkey were long Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). The biggest hedge fund stakeholder of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was John Overdeck and David Siegel’s Two Sigma Advisors with a stake worth about $215 million in the company.

Bronte Capital made the following comment about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q3 2022 investor letter:

“There have been some bright spots in our long book. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a major position and a stock we wrote up in our June 2021 letter, has been one of the best performing stocks in the S&P 500 this year. Alas it has not been enough to offset some of our weaker stocks, let alone our overweight exposure to the UK (and Europe) which have suffered from both stock and currency weakness. We do not think we are bad at picking stocks on the long side and hope – reasonably we think – for better relative results in the future. Prior to COVID, our longs were markedly better than the index. Unfortunately, if you look at our long book this quarter and since the onset of the COVID pandemic, there is scant evidence that we have added any value by picking stocks to go long.”